+

WO2000029033A3 - A method of genetic vector delivery - Google Patents

A method of genetic vector delivery Download PDF

Info

Publication number
WO2000029033A3
WO2000029033A3 PCT/US1999/027206 US9927206W WO0029033A3 WO 2000029033 A3 WO2000029033 A3 WO 2000029033A3 US 9927206 W US9927206 W US 9927206W WO 0029033 A3 WO0029033 A3 WO 0029033A3
Authority
WO
WIPO (PCT)
Prior art keywords
genetic vector
administering
vector delivery
patient
relates
Prior art date
Application number
PCT/US1999/027206
Other languages
French (fr)
Other versions
WO2000029033A2 (en
Inventor
E Antonio Chiocca
Keiro Ikeda
Raymond T Bartus
Original Assignee
Gen Hospital Corp
Alkermes Inc
E Antonio Chiocca
Keiro Ikeda
Raymond T Bartus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Alkermes Inc, E Antonio Chiocca, Keiro Ikeda, Raymond T Bartus filed Critical Gen Hospital Corp
Priority to AU19151/00A priority Critical patent/AU1915100A/en
Publication of WO2000029033A2 publication Critical patent/WO2000029033A2/en
Publication of WO2000029033A3 publication Critical patent/WO2000029033A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to a method of administering a genetic vector to a target cell in a patient by immunosuppressing the patient and administering the genetic vector. The invention also relates to a method of administering a genetic vector to a target cell in a patient by administering a complement inhibitor and the genetic vector. The invention also relates to further administering a blood-organ barrier modifier.
PCT/US1999/027206 1998-11-17 1999-11-17 A method of genetic vector delivery WO2000029033A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU19151/00A AU1915100A (en) 1998-11-17 1999-11-17 A method of genetic vector delivery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10888198P 1998-11-17 1998-11-17
US60/108,881 1998-11-17

Publications (2)

Publication Number Publication Date
WO2000029033A2 WO2000029033A2 (en) 2000-05-25
WO2000029033A3 true WO2000029033A3 (en) 2000-10-05

Family

ID=22324608

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/027206 WO2000029033A2 (en) 1998-11-17 1999-11-17 A method of genetic vector delivery

Country Status (2)

Country Link
AU (1) AU1915100A (en)
WO (1) WO2000029033A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4013900A (en) 1999-03-19 2000-10-09 Enos Pharmaceuticals, Inc. Increasing cerebral bioavailability of drugs
WO2007093036A1 (en) * 2006-02-13 2007-08-23 Oncolytics Biotech Inc. Use of local immune suppression to enhance oncolytic viral therapy
ES2831325T3 (en) * 2006-10-10 2021-06-08 Regenesance B V Complement inhibition for better nerve regeneration
WO2019032866A1 (en) * 2017-08-09 2019-02-14 Ohio State Innovation Foundation Oncolytic virus carrying e-cadherin and uses thereof
WO2021007111A1 (en) * 2019-07-05 2021-01-14 Apellis Pharmaceuticals, Inc. Viral vector therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004663A1 (en) * 1987-11-18 1989-06-01 State Of Oregon Acting By And Through The State Bo Method for the delivery of genetic material across the blood brain barrier
WO1996012406A1 (en) * 1994-10-19 1996-05-02 Genetic Therapy, Inc. Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004663A1 (en) * 1987-11-18 1989-06-01 State Of Oregon Acting By And Through The State Bo Method for the delivery of genetic material across the blood brain barrier
WO1996012406A1 (en) * 1994-10-19 1996-05-02 Genetic Therapy, Inc. Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BOUVET M ET AL: "Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide.", GENE THERAPY FEB., 1998, vol. 5, no. 2, February 1998 (1998-02-01), pages 189 - 195, XP000907596, ISSN: 0969-7128 *
CHRIST MARIELLE ET AL: "Gene therapy with recombinant adenovirus vectors: Evaluation of the host immune response.", IMMUNOLOGY LETTERS 1997, vol. 57, no. 1-3, 1997, pages 19 - 25, XP000907595, ISSN: 0165-2478 *
ELLIOTT PETER J ET AL: "Unlocking the blood-brain barrier: A role for RMP-7 in brain tumor therapy.", EXPERIMENTAL NEUROLOGY 1996, vol. 141, no. 2, 1996, pages 214 - 224, XP000907588, ISSN: 0014-4886 *
HOFMANN C ET AL: "Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system.", GENE THERAPY APRIL, 1998, vol. 5, no. 4, April 1998 (1998-04-01), pages 531 - 536, XP000914540, ISSN: 0969-7128 *
IKEDA KEIRO ET AL: "Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses.", NATURE MEDICINE AUG., 1999, vol. 5, no. 8, August 1999 (1999-08-01), pages 881 - 887, XP002139450, ISSN: 1078-8956 *
NILAVER: "delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption", PROC. NATL. ACAD SCI, vol. 92, 1995, pages 9829 - 9833, XP002139449 *
ROLLINS SCOTT A ET AL: "Protection of retroviral vector particles via complement inhibition: A novel strategy for in vivo gene therapy.", KEYSTONE SYMPOSIUM ON GENE THERAPY AND MOLECULAR MEDICINE;STEAMBOAT SPRINGS, COLORADO, USA; MARCH 26-APRIL 1, 1995, no. 21A, 1995, Journal of Cellular Biochemistry Supplement 1995, pages 413, XP002139447, ISSN: 0733-1959 *

Also Published As

Publication number Publication date
AU1915100A (en) 2000-06-05
WO2000029033A2 (en) 2000-05-25

Similar Documents

Publication Publication Date Title
WO1999042079A3 (en) Antimicrobial denture adhesive composition
WO1992018160A3 (en) Method for inhibiting adhesion of white blood cells to endothelial cells
GB9814527D0 (en) Delivery system
NO963283L (en) Non-viral vector
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
WO2003079972A3 (en) Active agent delivery systems and methods for protecting and administering active agents
AU2959595A (en) Camptothecin drug combinations and medicaments with reduced side effects
AU5743996A (en) Compositions and methods for nucleic acid delivery to the lu ng
IL145117A0 (en) Encapsulation of bioactive complexes in liposomes
AU7620200A (en) Compositions and methods relating to the inhibition of casomorphin and gluteomorphin
WO2003045309A3 (en) Peptides, peptide compositions,and methods of use in binding p 185
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
AU4830097A (en) Use of an extract of Cimicifuga
AU5658196A (en) Method for pharmaceutical delivery
AU6682594A (en) Treatment of septic shock
WO2000029033A3 (en) A method of genetic vector delivery
AU4651700A (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
GEP20063719B (en) Prevention of Migraine Recurrence
WO2000023587A3 (en) Gene therapy of alzheimer's disease by delivery of an encoded apolipoprotein e
WO2003106625A3 (en) Hammerhead ribozymes
WO2002098442A3 (en) Composition containing phytase
IL129368A0 (en) Immunogenic TLP composition
AU7439996A (en) Novel uses of mammalian ctla-8 and related reagents
HK1029919A1 (en) Method for preventing the misuse of a transdermal therapeutic system
WO2001001956A3 (en) Solid preparations containing paroxetine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载